HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

Middle East And Africa Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


Middle East And Africa Hepatic Encephalopathy Treatment Market Insights

  • Reed Intelligence analysis indicates that the Middle East And Africa Hepatic Encephalopathy Treatment Market size, which was USD 285.45 Million in 2025, is projected to attain USD 615.57 Million by 2034.
  • The market is expected to register a CAGR of 8.82% over the period 2026–2034.
  • In 2025, Rifaximin emerged as the dominant Drug Class based on market size.
  • Rifaximin is projected to register the fastest growth, positioning it as the most attractive Drug Class segment over the forecast horizon.

Other Key Findings


  • The global Hepatic Encephalopathy Treatment Market size saw Middle East And Africa holding a share of 11.51% in 2025.
  • United States is forecasted to account for the leading share of the global market by 2034.
  • In Middle East and Africa, Turkey is forecasted to be the fastest-expanding market, projected to reach USD 38.95 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 285.45 Million
Market Size In 2034 USD 615.57 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 8.82% (2026-2034)
Segmnetation Covered
Middle East and Africa
  1. United Arab Emirates
  2. Saudi Arabia
  3. South Africa
  4. Egypt
  5. Nigeria
  6. Turkey
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports